.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Cipla
Cantor Fitzgerald
Queensland Health
Medtronic
Novartis
Chubb
AstraZeneca
US Army
Julphar

Generated: June 24, 2017

DrugPatentWatch Database Preview

TIMOLOL MALEATE Drug Profile

« Back to Dashboard

Which patents cover Timolol Maleate, and what generic Timolol Maleate alternatives are available?

Timolol Maleate is a drug marketed by Usl Pharma, Apotex Inc, Akorn, Watson Labs, Pacific Pharma, Teva, Sandoz, Fdc Ltd, Sandoz Inc, Hi Tech Pharma, Quantum Pharmics, Fougera, Mylan, Wockhardt, and Bausch And Lomb. and is included in thirty-eight NDAs. There is one patent protecting this drug.

This drug has nineteen patent family members in eighteen countries.

The generic ingredient in TIMOLOL MALEATE is timolol maleate. There are fifteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the timolol maleate profile page.

Summary for Tradename: TIMOLOL MALEATE

Patents:1
Applicants:15
NDAs:38
Suppliers / Packagers: see list13
Bulk Api Vendors: see list56
Clinical Trials: see list325
Patent Applications: see list5,755
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TIMOLOL MALEATE at DailyMed

Pharmacology for Tradename: TIMOLOL MALEATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs
TIMOLOL MALEATE
timolol maleate
TABLET;ORAL072271-001Apr 11, 1989DISCNNoNo► Subscribe► Subscribe
Fougera
TIMOLOL MALEATE
timolol maleate
SOLUTION/DROPS;OPHTHALMIC074668-001Mar 25, 1997DISCNNoNo► Subscribe► Subscribe
Akorn
TIMOLOL MALEATE
timolol maleate
SOLUTION/DROPS;OPHTHALMIC074466-001Mar 25, 1997AT1RXNoNo► Subscribe► Subscribe
Mylan
TIMOLOL MALEATE
timolol maleate
TABLET;ORAL072668-002Jun 8, 1990RXNoNo► Subscribe► Subscribe
Quantum Pharmics
TIMOLOL MALEATE
timolol maleate
TABLET;ORAL072466-001May 19, 1989DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: TIMOLOL MALEATE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,261,547 Gelling ophthalmic compositions containing xanthan gum► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TIMOLOL MALEATE

Country Document Number Estimated Expiration
China1133466► Subscribe
European Patent Office1069913► Subscribe
Austria245451► Subscribe
Japan4545927► Subscribe
Spain2203103► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TIMOLOL MALEATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00C/001Belgium► SubscribePRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
C/GB99/043United Kingdom► SubscribePRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
/1999Austria► SubscribePRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
90041Netherlands► SubscribePRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
C0013Belgium► SubscribePRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Citi
Healthtrust
Cerilliant
Medtronic
Harvard Business School
Chubb
US Department of Justice
Colorcon
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot